Two case reports of tamoxifen as a cause of impotence in male subjects with carcinoma of the breast

Collinson, Michelle; Hamilton, DA; Tyrrell, C.J.

doi:10.1016/0960-9776(93)90037-g

Cited by 6 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early studies evaluating the efficacy of tamoxifen in male breast cancer reported few side effects to tamoxifen 23,24 . A later article reported 2 cases of impotence secondary to tamoxifen treatment 25 , but to our knowledge, only one study of tamoxifen toxicity in male breast cancer has been published 26 . Contrary to what had previously been reported, tamoxifen treatment in men with breast cancer was associated with a high rate of treatment-limiting side effects, with approximately 20% of patients discontinuing treatment prematurely.…”

Section: Resultsmentioning

confidence: 99%

“…The reports of decreased libido and of erectile dysfunction experienced by men treated with tamoxifen are interesting. It has been proposed that male sexual dysfunction with tamoxifen use is caused by decreased serum testosterone levels 25 . Future prospective studies evaluating the sexual dysfunction experienced by men taking endocrine therapy for breast cancer are needed.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Endocrine Therapy for Male Breast Cancer: Rates of Toxicity and Adherence

2010

View full text Add to dashboard Cite

Purpose: Most male breast cancer tumours are hormone receptor–positive; the patients therefore receive endocrine therapy. There is, however, a paucity of published data on toxicities experienced by male breast cancer patients who are prescribed endocrine therapy. In the present study, we examined rates of adherence to and toxicity from endocrine treatments in male breast cancer patients treated at a single institution. Patients and Methods: We conducted a retrospective study of male patients diagnosed with breast cancer at The Ottawa Hospital Cancer Centre during 1981–2003. Data collected included patient age, hormone receptor status, therapy adherence, self-reported toxicities, and type and duration of endocrine therapies. Results: The review located 59 cases of early-stage and metastatic male breast cancer. Median patient age was 68.0 years. Tamoxifen was given to 38 patients (64.4%), anastrozole to 8 (13.6%), and letrozole to 5 (8.5%). Of patients who received endocrine therapy, 10 (25%) received adjuvant systemic chemotherapy. Toxicity was reported by 19 patients taking tamoxifen (50%), with hot flashes being the most common complaint (18.4%). Decreased libido, weight gain, and malaise were reported by 5 patients (13.2%). Rash and erectile dysfunction were reported by 3 patients (7.9%). Increased liver enzymes, pulmonary embolism, superficial thrombophlebitis, myalgia, depression, visual blurring, and loose stools were each reported in 1 patient (2.6%). Tamoxifen therapy was discontinued secondary to toxicity in 9 patients (23.7%). Of the patients treated with anastrozole, 3 (37.5%) reported toxicity, with 1 report each of decreased libido, leg swelling, and depression (12.5%). Toxicity was reported in 2 patients taking letrozole (40%), with both reporting peripheral edema, and 1 reporting hot flashes. No patient discontinued anastrozole or letrozole because of toxicity. Conclusions: Few studies specifically report data on adherence to and toxicities from endocrine therapies in male breast cancer patients. The rate of discontinuation at our institution because of toxicity (23.7%) is similar to that reported in the female breast cancer population. Future prospective studies should explore strategies to improve adherence to endocrine therapy in this population.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Endocrine Therapy for Male Breast Cancer: Rates of Toxicity and Adherence

2010

View full text Add to dashboard Cite

show abstract

Tamoxifen adminstration is associated with a high rate of treatment‐limiting symptoms in male breast cancer patients

Anelli

Tran

et al. 1994

Cancer

159

View full text Add to dashboard Cite

Background. Although an uncommon disease, male breast cancer (MBC) will be responsible for 300 deaths in 1993 in the United States. Because of the high rate of estrogen receptor positivity in males, adjuvant hormonal therapy with tamoxifen in the adjuvant setting has been used widely. Little is known about the side effects of this estrogen receptor blocker in males. Methods. The authors evaluated the side effects of adjuvant tamoxifen treatment in 24 patients (19 of whom were estrogen receptor positive) treated at the authors' institution between 1990 and 1993. Results. Fifteen (62.5%) patients reported at least one side effect. The most common side effect was a decrease in libido, which occurred in 7 (29.2%) patients; followed by weight gain, which occurred in 6 (25%) patients; hot flashes, which occurred in (5 20.8%); mood alterations, which occurred in 5 (20.8%); depression, which occurred in 4 (16.6%); insomnia, which occurred in 3 (12.5%); and deep venous thrombosis, which occurred in 1 (4.2%). Five (20.8%) patients terminated treatment with tamoxifen in less than 1 year because of these side effects. Two of these patients had decreased libido, two had hot flashes, and one suffered deep venous thrombosis. Conclusions. In contrast to female breast cancer patients, who have a 4% attrition rate to adjuvant tamoxifen treatment, MBC patients have a 20.8% attrition rate related to side effects of tamoxifen treatment.

show abstract

Increased libido: a complication of tamoxifen therapy of male breast cancer

Delaney¹,

Langlands²

1996

The Breast

View full text Add to dashboard Cite

Two case reports of tamoxifen as a cause of impotence in male subjects with carcinoma of the breast

Cited by 6 publications

References 7 publications

Endocrine Therapy for Male Breast Cancer: Rates of Toxicity and Adherence

Endocrine Therapy for Male Breast Cancer: Rates of Toxicity and Adherence

Tamoxifen adminstration is associated with a high rate of treatment‐limiting symptoms in male breast cancer patients

Increased libido: a complication of tamoxifen therapy of male breast cancer

Contact Info

Product

Resources

About